Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
-
Stefano Zoccolella
Abstract
Background: Elevated plasma homocysteine (Hcy) concentrations are associated with increased risk of systemic vascular diseases, Alzheimer's disease and vascular dementia. Several cross-sectional reports and two prospective clinical studies have recently reported elevated plasma Hcy levels in L-dopa-treated Parkinson's disease (PD) patients and Hcy has been proposed as a possible mediator for the development of long-term L-dopa motor complications (such as wearing off and on-off phenomena, and dyskinesias). The aim of the study was to elucidate a possible role of L-dopa-related hyperhomocysteinemia in the development of dyskinesias.
Methods: In this cross-sectional study we compared Hcy, B12 and folate levels in 53 PD patients treated with L-dopa (29 with dyskinesias, 24 without dyskinesias).
Results: Mean plasma Hcy levels were higher in the group of PD patients with dyskinesias (19 vs. 15.4 T: 2.12; p=0.04). After taking into account potential confounding factors, analysis of the data revealed that the occurrence of dyskinesias progressively increased with plasma Hcy levels (relative risk 1.2, 95% CI 1.015–1.4; p=0.03).
Conclusions: Our results raise the possibility that Hcy plays a role in the development of dyskinesias, through its toxic effects on both dopaminergic neurons and non-substantia nigra, non-dopaminergic neurons.
Clin Chem Lab Med 2006;44:863–6.
References
1. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41:1392–403, Erratum Clin Chem Lab Med 2004; 42:113–6.10.1515/cclm.2004.42.1.113Search in Google Scholar
2. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2:425–8.10.1016/S1474-4422(03)00438-1Search in Google Scholar
3. Postuma RB, Lang A. Homocysteine and levodopa. Should Parkinson disease patients receive preventative therapy? Neurology 2004; 63:886–91.Search in Google Scholar
4. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levo-dopa and COMT inhibitors on plasma homocysteine in PD patients. Mov Disord 2005; 20:69–72.10.1002/mds.20261Search in Google Scholar
5. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108:66–7.10.1034/j.1600-0404.2003.00135.xSearch in Google Scholar
6. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19:1403–8.10.1002/mds.20253Search in Google Scholar
7. Muller T, Hefter H, Hueber R, Jost WH, Leenders KL, Odin P, et al. Is levodopa toxic? J Neurol 2004; 251(Suppl 6):44–6.10.1007/s00415-004-1610-xSearch in Google Scholar
8. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, editor. Quantification of neurologic deficit. Boston, MA: Butterworth-Heinemann, 1989:285–309.Search in Google Scholar
9. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565:441–6.10.1016/0378-4347(91)80407-4Search in Google Scholar
10. te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32:218–20.10.1177/000456329503200218Search in Google Scholar PubMed
11. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001; 24:313–23.10.1097/00002826-200111000-00002Search in Google Scholar PubMed
12. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80:101–10.10.1046/j.0022-3042.2001.00676.xSearch in Google Scholar PubMed
13. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behaviour in rodents. Neurotoxicology 2005; 26:361–71.10.1016/j.neuro.2005.01.008Search in Google Scholar
14. Gospe SM, Gietzen DW, Summers PJ, Lunetta JM, Miller JW, Selhub J, et al. Behavioural and neurochemical changes in folate-deficient mice. Physiol Behav 1995; 58:935–41.10.1016/0031-9384(95)00156-DSearch in Google Scholar
15. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26:137–46.10.1016/S0166-2236(03)00032-8Search in Google Scholar
16. Tjattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, Shea TB. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 2004; 3:71–6.10.1111/j.1474-9728.2004.00086.xSearch in Google Scholar PubMed
17. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997; 94:5923–8.10.1073/pnas.94.11.5923Search in Google Scholar PubMed PubMed Central
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Flow-cytometric immunophenotyping of normal and malignant lymphocytes
- Recommendation to treat continuous variable errors like attribute errors
- Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia
- Lack of association between α2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation – preliminary report
- Prognostic value of homocysteinemia in patients with congestive heart failure
- Comparability of indices for insulin resistance and insulin secretion determined during oral glucose tolerance tests
- Evaluation of clinical markers of atherosclerosis in young and elderly Japanese adults
- Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease
- Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates
- Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method
- Fluorimetric determination of activity and isoenzyme composition of N-acetyl-β-D-hexosaminidase in seminal plasma of fertile men and infertile patients with secretory azoospermia
- Increased fructosamine in non-diabetic rheumatoid arthritis patients: role of lipid peroxides and glutathione
- Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness – a multiparametric study in rats
- Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
- Use of total patient data for indirect estimation of reference intervals for 40 clinical chemical analytes in Turkey
- Use of haemolysis index to estimate potassium concentration in in-vitro haemolysed serum samples
- Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy
- Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer
- Evaluation and quality assessment of glucose concentration measurement in blood by point-of-care testing devices
- Hypothesis on interferences in kinetic interaction of microparticles in solution (KIMS) technology
- Comparability of point-of-care whole-blood electrolyte and substrate testing using a Stat Profile Critical Care Xpress analyzer and standard laboratory methods
- Determination of the length of sedimentation reaction in blood using the TEST 1 system: comparison with the Sedimatic 100 method, turbidimetric fibrinogen levels, and the influence of M-proteins
- Transcriptions and ISO 15189
- Falsely elevated troponin I attributed to inadequate centrifugation using the Access® immunoassay analyzer
- Interference of sulfamethoxazole in Capillarys® electrophoresis
Articles in the same Issue
- Flow-cytometric immunophenotyping of normal and malignant lymphocytes
- Recommendation to treat continuous variable errors like attribute errors
- Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia
- Lack of association between α2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation – preliminary report
- Prognostic value of homocysteinemia in patients with congestive heart failure
- Comparability of indices for insulin resistance and insulin secretion determined during oral glucose tolerance tests
- Evaluation of clinical markers of atherosclerosis in young and elderly Japanese adults
- Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease
- Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates
- Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method
- Fluorimetric determination of activity and isoenzyme composition of N-acetyl-β-D-hexosaminidase in seminal plasma of fertile men and infertile patients with secretory azoospermia
- Increased fructosamine in non-diabetic rheumatoid arthritis patients: role of lipid peroxides and glutathione
- Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness – a multiparametric study in rats
- Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
- Use of total patient data for indirect estimation of reference intervals for 40 clinical chemical analytes in Turkey
- Use of haemolysis index to estimate potassium concentration in in-vitro haemolysed serum samples
- Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy
- Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer
- Evaluation and quality assessment of glucose concentration measurement in blood by point-of-care testing devices
- Hypothesis on interferences in kinetic interaction of microparticles in solution (KIMS) technology
- Comparability of point-of-care whole-blood electrolyte and substrate testing using a Stat Profile Critical Care Xpress analyzer and standard laboratory methods
- Determination of the length of sedimentation reaction in blood using the TEST 1 system: comparison with the Sedimatic 100 method, turbidimetric fibrinogen levels, and the influence of M-proteins
- Transcriptions and ISO 15189
- Falsely elevated troponin I attributed to inadequate centrifugation using the Access® immunoassay analyzer
- Interference of sulfamethoxazole in Capillarys® electrophoresis
